BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

745 related articles for article (PubMed ID: 25934816)

  • 1. Toward precision medicine in glioblastoma: the promise and the challenges.
    Prados MD; Byron SA; Tran NL; Phillips JJ; Molinaro AM; Ligon KL; Wen PY; Kuhn JG; Mellinghoff IK; de Groot JF; Colman H; Cloughesy TF; Chang SM; Ryken TC; Tembe WD; Kiefer JA; Berens ME; Craig DW; Carpten JD; Trent JM
    Neuro Oncol; 2015 Aug; 17(8):1051-63. PubMed ID: 25934816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioblastoma targeted therapy: updated approaches from recent biological insights.
    Touat M; Idbaih A; Sanson M; Ligon KL
    Ann Oncol; 2017 Jul; 28(7):1457-1472. PubMed ID: 28863449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.
    Bastien JI; McNeill KA; Fine HA
    Cancer; 2015 Feb; 121(4):502-16. PubMed ID: 25250735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
    Daher A; de Groot J
    Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.
    Venkatesan S; Lamfers ML; Dirven CM; Leenstra S
    CNS Oncol; 2016; 5(2):77-90. PubMed ID: 26986934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SnapShot: glioblastoma multiforme.
    Kotliarova S; Fine HA
    Cancer Cell; 2012 May; 21(5):710-710.e1. PubMed ID: 22624719
    [No Abstract]   [Full Text] [Related]  

  • 7. Toward Personalized Targeted Therapeutics: An Overview.
    Weathers SS; Gilbert MR
    Neurotherapeutics; 2017 Apr; 14(2):256-264. PubMed ID: 27995437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using the molecular classification of glioblastoma to inform personalized treatment.
    Olar A; Aldape KD
    J Pathol; 2014 Jan; 232(2):165-77. PubMed ID: 24114756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
    Coyne GO; Takebe N; Chen AP
    Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma precision therapy: From the bench to the clinic.
    Zhou Y; Wu W; Bi H; Yang D; Zhang C
    Cancer Lett; 2020 Apr; 475():79-91. PubMed ID: 32004571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.
    Coleman N; Ameratunga M; Lopez J
    Clin Med Insights Oncol; 2018; 12():1179554918759079. PubMed ID: 29511362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI study identifies three subtypes of glioblastoma.
    Brower V
    Lancet Oncol; 2015 Oct; 16(13):e484. PubMed ID: 26365415
    [No Abstract]   [Full Text] [Related]  

  • 13. The challenges associated with molecular targeted therapies for glioblastoma.
    Jue TR; McDonald KL
    J Neurooncol; 2016 May; 127(3):427-34. PubMed ID: 26900075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of molecular profiling on clinical trial design for glioblastoma.
    Chakravarti A; Tyndall E; Palanichamy K; Mehta M; Aldape K; Loeffler J
    Curr Oncol Rep; 2007 Jan; 9(1):71-9. PubMed ID: 17164051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using genomics to guide treatment for glioblastoma.
    Young JS; Prados MD; Butowski N
    Pharmacogenomics; 2018 Oct; 19(15):1217-1229. PubMed ID: 30203716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glioblastoma: molecular analysis and clinical implications.
    Huse JT; Holland E; DeAngelis LM
    Annu Rev Med; 2013; 64():59-70. PubMed ID: 23043492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
    Weller M; Wick W; Hegi ME; Stupp R; Tabatabai G
    Future Oncol; 2010 Sep; 6(9):1407-14. PubMed ID: 20919826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.
    Gan HK; van den Bent M; Lassman AB; Reardon DA; Scott AM
    Nat Rev Clin Oncol; 2017 Nov; 14(11):695-707. PubMed ID: 28675164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targets in glioblastoma.
    Zorzan M; Giordan E; Redaelli M; Caretta A; Mucignat-Caretta C
    Future Oncol; 2015; 11(9):1407-20. PubMed ID: 25952786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One size should not fit all: advancing toward personalized glioblastoma therapy.
    Reardon DA; Ligon KL; Chiocca EA; Wen PY
    Discov Med; 2015 Jun; 19(107):471-7. PubMed ID: 26175405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.